6 in 10 Austrialians in care take antidepressants … Pneumococcal shot could do double duty to fight viral respiratory infections … Study: Rebounds occurred with both COVID-19 antivirals … Quest stops...
Report: 1 in 5 will rebound after Paxlovid, but it still works
By
Kristen Fischer
Nov 14, 2023
One in five people who take nirmatrelvir/ritonavir (Paxlovid) get COVID-19 again after the drug clears them of it, according to a new study.
FDA advisers support full approval of Paxlovid for at-risk older adults
By
Alicia Lasek
Mar 16, 2023
The antiviral drug Paxlovid should receive full FDA approval to treat COVID-19 in older adults at risk of severe outcomes, the advisers decided in a Thursday vote.
Paxlovid cuts COVID hospitalization, which may leave older adults weakened
By
Alicia Lasek
Dec 02, 2022
The CDC reports that COVID patients treated with the antiviral Paxlovid have a 51% lower risk of hospitalization, while another study has tied acute-care stays to muscle loss and long COVID.
Stanford to test antiviral pills as long COVID treatment
By
Alicia Lasek
Nov 28, 2022
Investigators plan to test whether the antiviral drug Paxlovid will relieve symptoms of the syndrome known as long COVID, also called post-acute sequelae of COVID-19.